 | • レポートコード：MRC2203A058 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、世界の気管支炎治療市場規模が、年平均3.6％成長すると予測しています。本市場調査レポートでは、気管支炎治療の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤クラス別（抗生物質、抗炎症薬、気管支拡張薬、その他）分析、エンドユーザー別（病院薬局、小売薬局、その他）分析、種類別（急性気管支炎、慢性気管支炎）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の気管支炎治療市場規模：薬剤クラス別（抗生物質、抗炎症薬、気管支拡張薬、その他） ・世界の気管支炎治療市場規模：エンドユーザー別（病院薬局、小売薬局、その他） ・世界の気管支炎治療市場規模：種類別（急性気管支炎、慢性気管支炎） ・世界の気管支炎治療市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（AstraZeneca plc、Novartis AG、GlaxoSmithKline plc、…） ・市場機会・将来傾向 |
The bronchitis treatment market studied was anticipated to grow with a CAGR of 3.6% over the forecast period. The major factor attributing to the growth of the bronchitis treatment market is a large patient pool with COPD diseases. According to CDC (Centres for Disease Control and Prevention) in 2018, 9.0 million adults got diagnosed with chronic bronchitis and there are few more factors which are playing pivotal roles in taking the bronchitis treatment market to the next level such as an increase in geriatric population with increased prevalence of bronchitis, rise in habits like smoking and increased levels of chemical pollutants.
According to the recent report from COPD foundation.org smoking is associated with 90 percent of all COPD deaths in the United States. Thus, all of the above mentioned factors are expected to drive the growth of the market.
Key Market Trends
Bronchodilators is the Expected to Show a High Growth During the Forecast Period
Bronchodilators are drugs that open the airway passages and are also used for expanding the windpipe, thus improving the breathing of the individuals suffering from lung infections, bronchial asthma, and chronic obstructive pulmonary disease (COPD). Bronchodilators are the first-line medication for the treatment of bronchitis for clearing the airway obstruction, which is an essential thing in chronic bronchitis to ease the breathing of the patient.
The major factors, such as increasing incidence of respiratory diseases and the rising prevalence of smoking, are driving the growth of the market segment. Therefore, as the number of respiratory diseases is increasing, there is a demand for bronchodilators.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall bronchitis treatment market throughout the forecast period. This is due to factors such as the rising incidence of bronchitis and an increasing trend of smoking in the young generation.
In the North America region, the United States holds the largest market share due to factors such as a growing number of geriatric populations, along with an increasing number of diseases in the country, well-established insurance policies and the availability of advanced healthcare infrastructure are few of the major factors, which is anticipated to stimulate the demand in this region. According to the Centers for Disease Control and Prevention (CDC), 9.0 million adults were diagnosed with Chronic bronchitis in the United States for the year 2017, and the incidence of the disease is rising which further increases the market growth.
Competitive Landscape
The bronchitis treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Melinta Therapeutics, Sanofi S.A, and Boehringer Ingelheim International GmbH, and Pfizer Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Geriatric Population with Increased Incidence of Bronchitis
4.2.2 Increased Prevalence of COPD Cases
4.2.3 Increased Smoking and Rising Levels of Chemical Pollutants
4.3 Market Restraints
4.3.1 Patent Expiry of Key Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Class of Drugs
5.1.1 Antibiotics
5.1.2 Anti-inflammatory Drugs
5.1.3 Bronchodilator
5.1.4 Other
5.2 By End User
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Other
5.3 By Type
5.3.1 Acute Bronchitis
5.3.2 Chronic Bronchitis
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca plc
6.1.2 Novartis AG
6.1.3 GlaxoSmithKline plc
6.1.4 Dr. Reddy’s Laboratories Ltd.
6.1.5 Sanofi S.A
6.1.6 Boehringer Ingelheim International GmbH
6.1.7 Pfizer Inc.
6.1.8 Melinta Therapeutics
7 MARKET OPPORTUNITIES AND FUTURE TRENDS